BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 19594950)

  • 1. Synergistic antitumor activity of oncolytic reovirus and chemotherapeutic agents in non-small cell lung cancer cells.
    Sei S; Mussio JK; Yang QE; Nagashima K; Parchment RE; Coffey MC; Shoemaker RH; Tomaszewski JE
    Mol Cancer; 2009 Jul; 8():47. PubMed ID: 19594950
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SMAC mimetic (JP1201) sensitizes non-small cell lung cancers to multiple chemotherapy agents in an IAP-dependent but TNF-α-independent manner.
    Greer RM; Peyton M; Larsen JE; Girard L; Xie Y; Gazdar AF; Harran P; Wang L; Brekken RA; Wang X; Minna JD
    Cancer Res; 2011 Dec; 71(24):7640-8. PubMed ID: 22049529
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interaction between gemcitabine and topotecan in human non-small-cell lung cancer cells: effects on cell survival, cell cycle and pharmacogenetic profile.
    Giovannetti E; Mey V; Danesi R; Basolo F; Barachini S; Deri M; Del Tacca M
    Br J Cancer; 2005 Feb; 92(4):681-9. PubMed ID: 15700043
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination therapy of poly (ADP-ribose) polymerase inhibitor 3-aminobenzamide and gemcitabine shows strong antitumor activity in pancreatic cancer cells.
    Jacob DA; Bahra M; Langrehr JM; Boas-Knoop S; Stefaniak R; Davis J; Schumacher G; Lippert S; Neumann UP
    J Gastroenterol Hepatol; 2007 May; 22(5):738-48. PubMed ID: 17444865
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical studies of gemcitabine and trastuzumab in breast and lung cancer cell lines.
    Hirsch FR; Helfrich B; Franklin WA; Varella-Garcia M; Chan DC; Bunn PA
    Clin Breast Cancer; 2002 May; 3 Suppl 1():12-6. PubMed ID: 12057039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I/II trial of carboplatin and paclitaxel chemotherapy in combination with intravenous oncolytic reovirus in patients with advanced malignancies.
    Karapanagiotou EM; Roulstone V; Twigger K; Ball M; Tanay M; Nutting C; Newbold K; Gore ME; Larkin J; Syrigos KN; Coffey M; Thompson B; Mettinger K; Vile RG; Pandha HS; Hall GD; Melcher AA; Chester J; Harrington KJ
    Clin Cancer Res; 2012 Apr; 18(7):2080-9. PubMed ID: 22316603
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The human immunodeficiency virus protease inhibitor ritonavir inhibits lung cancer cells, in part, by inhibition of survivin.
    Srirangam A; Milani M; Mitra R; Guo Z; Rodriguez M; Kathuria H; Fukuda S; Rizzardi A; Schmechel S; Skalnik DG; Pelus LM; Potter DA
    J Thorac Oncol; 2011 Apr; 6(4):661-70. PubMed ID: 21270666
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antitumor activity of lobaplatin alone or in combination with antitubulin agents in non-small-cell lung cancer.
    Xie CY; Xu YP; Jin W; Lou LG
    Anticancer Drugs; 2012 Aug; 23(7):698-705. PubMed ID: 22441567
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of docetaxel in advanced non-small-cell lung cancer.
    Belani CP; Eckardt J
    Lung Cancer; 2004 Dec; 46 Suppl 2():S3-11. PubMed ID: 15698529
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized phase II trial of sequential chemotherapy in advanced non-small cell lung cancer (SWOG 9806): carboplatin/gemcitabine followed by paclitaxel or cisplatin/vinorelbine followed by docetaxel.
    Edelman MJ; Clark JI; Chansky K; Albain K; Bhoopalam N; Weiss GR; Giguere JK; Kelly K; Crowley J; Gandara DR
    Clin Cancer Res; 2004 Aug; 10(15):5022-6. PubMed ID: 15297403
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of Her-2/neu in human lung cancer cell lines by immunohistochemistry and fluorescence in situ hybridization and its relationship to in vitro cytotoxicity by trastuzumab and chemotherapeutic agents.
    Bunn PA; Helfrich B; Soriano AF; Franklin WA; Varella-Garcia M; Hirsch FR; Baron A; Zeng C; Chan DC
    Clin Cancer Res; 2001 Oct; 7(10):3239-50. PubMed ID: 11595720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic cytotoxicity of oncolytic reovirus in combination with cisplatin-paclitaxel doublet chemotherapy.
    Roulstone V; Twigger K; Zaidi S; Pencavel T; Kyula JN; White C; McLaughlin M; Seth R; Karapanagiotou EM; Mansfield D; Coffey M; Nuovo G; Vile RG; Pandha HS; Melcher AA; Harrington KJ
    Gene Ther; 2013 May; 20(5):521-8. PubMed ID: 22895509
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer.
    Heinemann L; Simpson GR; Boxall A; Kottke T; Relph KL; Vile R; Melcher A; Prestwich R; Harrington KJ; Morgan R; Pandha HS
    BMC Cancer; 2011 Jun; 11():221. PubMed ID: 21645351
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interactions of gemcitabine, carboplatin and paclitaxel in molecularly defined non-small-cell lung cancer cell lines.
    Edelman MJ; Quam H; Mullins B
    Cancer Chemother Pharmacol; 2001 Aug; 48(2):141-4. PubMed ID: 11561780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Arsenic trioxide exerts synergistic effects with cisplatin on non-small cell lung cancer cells via apoptosis induction.
    Li H; Zhu X; Zhang Y; Xiang J; Chen H
    J Exp Clin Cancer Res; 2009 Aug; 28(1):110. PubMed ID: 19664237
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paclitaxel efficacy is increased by parthenolide via nuclear factor-kappaB pathways in in vitro and in vivo human non-small cell lung cancer models.
    Gao ZW; Zhang DL; Guo CB
    Curr Cancer Drug Targets; 2010 Nov; 10(7):705-15. PubMed ID: 20578985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synergy of a herpes oncolytic virus and paclitaxel for anaplastic thyroid cancer.
    Lin SF; Gao SP; Price DL; Li S; Chou TC; Singh P; Huang YY; Fong Y; Wong RJ
    Clin Cancer Res; 2008 Mar; 14(5):1519-28. PubMed ID: 18316577
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergistic induction of apoptosis by the combination of trail and chemotherapy in chemoresistant ovarian cancer cells.
    Cuello M; Ettenberg SA; Nau MM; Lipkowitz S
    Gynecol Oncol; 2001 Jun; 81(3):380-90. PubMed ID: 11371126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PARP inhibition selectively increases sensitivity to cisplatin in ERCC1-low non-small cell lung cancer cells.
    Cheng H; Zhang Z; Borczuk A; Powell CA; Balajee AS; Lieberman HB; Halmos B
    Carcinogenesis; 2013 Apr; 34(4):739-49. PubMed ID: 23275151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.
    Clegg A; Scott DA; Sidhu M; Hewitson P; Waugh N
    Health Technol Assess; 2001; 5(32):1-195. PubMed ID: 12065068
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.